Loading...
NPI 1073775342 · Reno, NV · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Elena Geraymovych is a ophthalmology physician provider located in Reno, Nevada. This profile covers 21 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Elena Geraymovych |
| Address | 610 Sierra Rose Dr |
| City | Reno |
| State | NV |
| ZIP | 89511 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 27, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.1M |
| Medicaid | $16.9K |
ELENA GERAYMOVYCH's Medicare billing is heavily dominated by intravitreal anti-VEGF therapy, with J0178 (aflibercept) and J2777 (faricimab-svoa) together accounting for the majority of her Medicare revenue; the precomputed top-3 Medicare codes generate 90.8% of total Medicare revenue, highlighting a practice concentrated on retinal injectable therapeutics and related procedures. This code mix indicates an ophthalmology practice primarily delivering medical retina services (frequent intravitreal injections and associated retinal imaging/interventions) rather than broad general ophthalmology.
Revenue concentration is extreme on Medicare: J0178 alone accounts for $2.3M and 55.9% of this provider’s Medicare revenue, and the top 3 Medicare codes collectively represent 90.8% of Medicare revenue, signaling that the provider’s financial performance is highly dependent on a small set of high-value retinal care services. For Medicaid, the top 3 codes likewise concentrate revenue, with those codes producing 91.7% of total Medicaid revenue, so both payer streams are tightly focused on the same procedure types.
Despite performing high-volume injections, the provider’s competitive standing varies by code: J0178 ranks #129 of 3204 nationally (96th percentile) and is described as notably above typical national volume, indicating the provider is a major national-volume reporter for aflibercept. J2777 ranks #154 of 2039 (92nd percentile) at a high national position as well, while 67028 ranks #217 of 4255 (95th percentile) and is also notably above typical volume, supporting a profile of above-typical procedural throughput for retinal injections and related procedural care.
There are several extreme and notable statistical outliers in the provider’s Medicare mix that reflect specialized imaging and treatment volume: 92134 (retinal OCT imaging) is listed as an extreme outlier and ranks #564 of 26868 providers nationally (98th percentile), and 92250 (fundus photography) ranks in the 97th percentile; these high ranks for diagnostic imaging codes reinforce that the practice combines frequent intravitreal therapy with substantial retinal imaging capacity. These outlier labels imply the provider is performing imaging at volumes far above typical peers, consistent with a retina-focused clinical operation.
Payer mix is highly Medicare-dominant in scale: lifetime Medicare revenue is $4.1M compared with lifetime Medicaid revenue of $16.9K, so the provider is effectively a Medicare-focused practice with only a modest Medicaid footprint. While Medicaid activity exists and mirrors the Medicare service mix (top Medicaid codes include 92012, 92134, and 67028 and the top 3 account for 91.7% of Medicaid revenue), Medicaid contributes a very small share of lifetime revenue and is not a material source of income relative to Medicare.
Within the in-state Medicaid context this provider is a mid-tier participant for the reported Medicaid codes: 92012 ranks #24 of 43 providers in-state (45th percentile) and 92134 ranks #20 of 40 (51st percentile), indicating typical, unremarkable state-level volumes for those services despite the provider’s high national standing on some Medicare codes. This suggests the practice’s strong Medicare volumes are not mirrored by dominant Medicaid market share locally.
Clinical tenure supports an established practice presence: the NPI was enumerated on 2008-06-27 (approximately 18 years ago), which is consistent with an experienced ophthalmologist likely to have developed a focused retina service line over time. That longevity, combined with concentrated billing on high-volume injection and retinal imaging codes, is consistent with a stable specialty practice rather than a recently established or generalized ophthalmology clinic.
Procedure and E/M billing are secondary to procedure/injectable revenue: standard E/M and common ophthalmic office visit codes such as 99213, 99214, 92014, and 92004 appear in the Medicare top codes but represent relatively small shares of revenue compared with injectables and retinal imaging. This mix supports the interpretation that most patient encounters are procedure-driven visits tied to ongoing treatment regimens (injections and imaging) rather than routine primary ophthalmic care.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,320 | $690 | $2.3M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 41,460 | $30 | $1.2M |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,390 | $100 | $227.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,670 | $30 | $77.4K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 460 | $160 | $71.9K |
| J9035 | Injection, bevacizumab, 10 mg | 570 | $50 | $30.1K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 330 | $80 | $27.1K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 410 | $70 | $26.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 260 | $100 | $24.6K |
| 67041 | In this procedure, the provider removes scar tissue from the retinal membrane that obscures vision. He removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical… | 30 | $890 | $24.1K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 1 | 20 | 830 | $690 | $671.6K |
| J2777 | 2 | 10 | 7,020 | $30 | $616.8K |
| 67028 | 2 | 30 | 670 | $90 | $72.3K |
| J7312 | 2 | 10 | 380 | $160 | $68.5K |
| 67108 | 3 | 10 | 20 | $1,100 | $24.3K |
| 67036 | 2 | 10 | 30 | $950 | $20.8K |
| 67041 | 1 | 10 | 20 | $880 | $19.3K |
| 99214 | 973 | 3,610 | 110 | $80 | $19K |
| J9035 | 3 | 20 | 230 | $50 | $15.6K |
| 92014 | 41 | 290 | 90 | $80 | $15.2K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 100 | $60 | $6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 220 | $30 | $5.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 120 | $30 | $3.8K |
| J0178 | Injection, aflibercept, 1 mg | 10 | $100 | $1.4K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 6 | 10 | 590 | $810 | $453.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 9 | 10 | 140 | $50 | $117.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 20 | 40 | 210 | $20 | $47.3K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 24 | 40 | 170 | $30 | $22.8K |
Other providers in the same ZIP code as Elena Geraymovych, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.